NLGP Attenuates Murine Melanoma and Carcinoma Metastasis by Modulating Cytotoxic CD8
B16F10
CD8+ T cells
LLC
NLGP
antigen presentation
dendritic cells
metastasis
metastatic colonization
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2020
2020
Historique:
received:
12
09
2019
accepted:
05
02
2020
entrez:
27
3
2020
pubmed:
27
3
2020
medline:
27
3
2020
Statut:
epublish
Résumé
Neem leaf glycoprotein (NLGP), a natural immunomodulator, attenuates murine carcinoma and melanoma metastasis, independent of primary tumor growth and alterations in basic cellular properties (cell proliferation, cytokine secretion, etc.). Colonization event of invasion-metastasis cascade was primarily inhibited by NLGP, with no effect on metastasis-related invasion, migration, and extravasation. High infiltration of interferon γ (IFN-γ)-secreting cytotoxic CD8
Identifiants
pubmed: 32211313
doi: 10.3389/fonc.2020.00201
pmc: PMC7076076
doi:
Types de publication
Journal Article
Langues
eng
Pagination
201Informations de copyright
Copyright © 2020 Bhuniya, Guha, Ganguly, Saha, Dasgupta, Nandi, Das, Ghosh, Ghosh, Haque, Banerjee, Bose and Baral.
Références
Nature. 2007 Dec 6;450(7171):903-7
pubmed: 18026089
Science. 2008 Jan 11;319(5860):195-8
pubmed: 18187653
J Clin Invest. 2010 Jun;120(6):2030-9
pubmed: 20501944
Cancer Immunol Res. 2017 Dec;5(12):1062-1073
pubmed: 29097419
PLoS One. 2017 May 10;12(5):e0177365
pubmed: 28489886
Cancer Cell. 2008 May;13(5):394-406
pubmed: 18455123
Science. 2016 Apr 8;352(6282):169-75
pubmed: 27124450
PLoS One. 2013;8(1):e47434
pubmed: 23326300
Nat Med. 2006 Aug;12(8):895-904
pubmed: 16892035
Nat Rev Immunol. 2008 Sep;8(9):675-84
pubmed: 19172690
Cancer Cell. 2018 Apr 9;33(4):547-562
pubmed: 29634943
Nat Rev Cancer. 2011 Feb;11(2):135-41
pubmed: 21258397
J Am Chem Soc. 2010 Mar 10;132(9):3224-8
pubmed: 20155906
Cell. 2017 Feb 9;168(4):670-691
pubmed: 28187288
Cell Death Dis. 2015 Jun 18;6:e1792
pubmed: 26086965
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Nat Rev Cancer. 2015 Apr;15(4):238-47
pubmed: 25801619
Cancer Immunol Res. 2014 May;2(5):487-500
pubmed: 24795361
Oncoimmunology. 2012 Aug 1;1(5):751-753
pubmed: 22934271
Cancer Cell. 2006 Mar;9(3):189-98
pubmed: 16530703
Eur J Immunol. 2017 May;47(5):872-879
pubmed: 28295265
Nature. 2016 Jan 21;529(7586):298-306
pubmed: 26791720
J Immunol. 2015 Nov 15;195(10):5055-65
pubmed: 26453753
J Immunol. 2009 Oct 1;183(7):4378-84
pubmed: 19734208
Cancer Res. 2010 Feb 15;70(4):1544-54
pubmed: 20145120
Lancet. 2007 May 19;369(9574):1742-57
pubmed: 17512859
Nat Immunol. 2004 Mar;5(3):328-36
pubmed: 14973437
Science. 2008 Jan 11;319(5860):163-4
pubmed: 18187643
Mol Immunol. 2016 Mar;71:42-53
pubmed: 26851529
Methods Mol Biol. 2012;928:221-8
pubmed: 22956145
Nature. 2016 Mar 24;531(7595):513-7
pubmed: 26982733
Cell. 2011 Oct 14;147(2):275-92
pubmed: 22000009
PLoS One. 2014 Nov 12;9(11):e110040
pubmed: 25391149
Expert Opin Drug Metab Toxicol. 2016;12(1):57-75
pubmed: 26565919
Nat Chem Biol. 2010 Mar;6(3):209-217
pubmed: 20118940
Nature. 2005 Dec 8;438(7069):820-7
pubmed: 16341007
Blood. 2008 Dec 15;112(13):4971-80
pubmed: 18818389
Int J Cancer. 2003 Jan 10;103(2):205-11
pubmed: 12455034
Nat Clin Pract Oncol. 2008 Apr;5(4):206-19
pubmed: 18253104
Nat Commun. 2016 Aug 05;7:12368
pubmed: 27492902
Lab Invest. 2017 Jun;97(6):669-697
pubmed: 28346400
Cancer Res. 2006 Dec 1;66(23):11089-93
pubmed: 17145848
Nat Rev Cancer. 2002 Aug;2(8):563-72
pubmed: 12154349
Blood. 2002 Sep 1;100(5):1728-33
pubmed: 12176894
PLoS One. 2013 Jun 13;8(6):e66501
pubmed: 23785504
Int J Cancer. 2016 Nov 1;139(9):2068-81
pubmed: 27405489
Crit Rev Oncog. 2015;20(3-4):301-14
pubmed: 26349421
Front Immunol. 2018 Jul 31;9:1787
pubmed: 30108595
J Exp Med. 2013 Aug 26;210(9):1855-69
pubmed: 23960189